Abstract
Serotonin4 (5-HT4) receptors have been shown to be involved in several peripheral and central functions, including control of the gastro-intestinal tract, modulation of memory and food intake, as well as positive regulation of the release of various neurotransmitters. Recently, we have proposed that the study of these receptors may also bring a new hope for treating depression, their agonists possibly acting as fast-acting antidepressants. This hypothesis was based on several studies showing that 5-HT4 receptors play an important role in the modulation of central 5-HT neurotransmission, both at pre- and postsynaptic levels. The possible physiological meaning of this control is discussed, together with the different research perspectives opened by its discovery.
Keywords: Depression, 5-HT neurons, 5-HT4 receptors, fast-acting antidepressants, dorsal raphe nucleus, modulation of mood
Current Drug Targets
Title: Serotonin Receptors, Type 4: A New Hope?
Volume: 10 Issue: 11
Author(s): Guillaume Lucas
Affiliation:
Keywords: Depression, 5-HT neurons, 5-HT4 receptors, fast-acting antidepressants, dorsal raphe nucleus, modulation of mood
Abstract: Serotonin4 (5-HT4) receptors have been shown to be involved in several peripheral and central functions, including control of the gastro-intestinal tract, modulation of memory and food intake, as well as positive regulation of the release of various neurotransmitters. Recently, we have proposed that the study of these receptors may also bring a new hope for treating depression, their agonists possibly acting as fast-acting antidepressants. This hypothesis was based on several studies showing that 5-HT4 receptors play an important role in the modulation of central 5-HT neurotransmission, both at pre- and postsynaptic levels. The possible physiological meaning of this control is discussed, together with the different research perspectives opened by its discovery.
Export Options
About this article
Cite this article as:
Lucas Guillaume, Serotonin Receptors, Type 4: A New Hope?, Current Drug Targets 2009; 10 (11) . https://dx.doi.org/10.2174/138945009789735200
DOI https://dx.doi.org/10.2174/138945009789735200 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cholinergic System Dysfunction and Neurodegenerative Diseases: Cause or Effect?
CNS & Neurological Disorders - Drug Targets NPY Y2 and Y4 Receptors Selective Ligands: Promising Anti-Obesity Drugs?
Current Topics in Medicinal Chemistry Freezing of Gait in Parkinsonism and its Potential Drug Treatment
Current Neuropharmacology Copper Status Abnormalities and How to Measure Them in Neurodegenerative Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Current Neuropharmacology G Protein-Activated Inwardly Rectifying Potassium Channels as Potential Therapeutic Targets
Current Pharmaceutical Design Quantitative Gait Disturbances in Older Adults with Cognitive Impairments
Current Pharmaceutical Design Influence of Lithium Treatment on GDNF Serum and CSF Concentrations in Patients with Early Alzheimers Disease
Current Alzheimer Research Neurotuberculosis: An Overview
Central Nervous System Agents in Medicinal Chemistry The Antioxidant Response as a Drug Target in Diabetic Neuropathy
Current Drug Targets The Effects of P75NTR on Learning Memory Mediated by Hippocampal Apoptosis and Synaptic Plasticity
Current Pharmaceutical Design C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Current Neuropharmacology Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Cognitive Effects of Nicotine: Recent Progress
Current Neuropharmacology Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology
Current Pharmaceutical Design 123I-Ioflupane SPECT and 18F-FDG PET Combined Use in the Characterization of Movement and Cognitive Associated Disorders in Neurodegenerative Diseases
Current Alzheimer Research Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Drug-Induced Impulse Control Disorders: A Review
Current Clinical Pharmacology Radiopharmaceuticals in Neurological and Psychiatric Disorders
Current Clinical Pharmacology A Translational View of Peptide Treatment of Neurological Disorders
Current Medicinal Chemistry